India approves AstraZeneca and local Covid vaccines, rollout in weeks

Published January 3, 2021
Vials of AstraZeneca's Covishield, coronavirus disease vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, Nov 30, 2020. — Reuters
Vials of AstraZeneca's Covishield, coronavirus disease vaccine, are seen before they are packaged inside a lab at Serum Institute of India, Pune, Nov 30, 2020. — Reuters

India’s drugs regulator on Sunday gave final approval for the emergency use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech.

The world’s second most populous country is now expected to start a massive immunisation programme within weeks, with the AstraZeneca/Oxford shot taking the lead and Bharat Biotech’s Covaxin administered under stricter conditions given that no efficacy data has been released for it.

The overall efficacy of the AstraZeneca/Oxford vaccine was 70.42 per cent, while Bharat Biotech’s Covaxin was “safe and provides a robust immune response”, said Drugs Controller General of India VG Somani.

The British-developed AstraZeneca/Oxford shot is being made locally by the Serum Institute of India (SII) and will be branded Covishield, while Bharat Biotech has teamed up with the government run Indian Council of Medical Research.

“Vaccines of Serum [Institute of India] and Bharat Biotech are being approved for restricted use in emergency situations,” Somani read out from a written statement at a press conference. Somani did not take questions.

Both vaccines will be administered in two doses and stored at two to eight degrees Celsius, he said. Sources told Reuters on Saturday the doses would have to be given four weeks apart.

Somani explained that the Bharat Biotech vaccine had been approved “in public interest as an abundant precaution, in clinical trial mode, to have more options for vaccinations, especially in case of infection by mutant strains”.

Prime Minister Narendra Modi welcomed the approvals.

“It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India!” he said on Twitter, calling it a sign of a “self-reliant” country.

SII, the world’s biggest vaccine producer, has already stockpiled more than 50 million doses of the AstraZeneca/Oxford vaccine even without a formal supply deal with the government.

“All the risks Serum Institute of India took with stockpiling the vaccine, have finally paid off,” CEO Adar Poonawalla said on Twitter. “Covishield, India’s first Covid-19 vaccine, is approved, safe, effective and ready to roll out in the coming weeks.”

Opinion

Moral panic
18 Oct 2021

Moral panic

The PM and others perhaps see decay through the growth of entertainment and fashion industries.
Challenges amid discord
18 Oct 2021

Challenges amid discord

Institutional disharmony and polarised politics are impeding efforts to address the country’s challenges.
Climate & youth
Updated 17 Oct 2021

Climate & youth

Disillusionment and anxiety are on the rise among youth as they confront the diminishing prospects of a better tomorrow.

Editorial

18 Oct 2021

Financial troubles

THE PTI administration has found itself left with no option but to go back to the IMF with a request for the...
18 Oct 2021

Complaint portal

IN a ruling on Thursday, the Mingora bench of the Peshawar High Court held that the Prime Minister’s Performance...
18 Oct 2021

Capital’s master plan

IT is encouraging that on Thursday, the restructured commission formed by the federal cabinet to revise ...
Carnage in Kandahar
Updated 17 Oct 2021

Carnage in Kandahar

Pakistan’s anti-extremism policy is in many ways half-baked and inconsistent.
17 Oct 2021

Sanctity of contracts

PAKISTAN is facing yet another international dispute before the International Centre for Settlement of Investment...
17 Oct 2021

New sports policy

THIS week, the Pakistan Football Federation Normalisation Committee chief Haroon Malik was in Zurich to hold ...